Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Allergies, especially dust mite allergy, may worsen alopecia areata, and desensitization could help reduce its severity.

T cell subsets are crucial in kidney cancer, and a new model predicts patient outcomes using key genes.

Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.

Hair growth phase in mice weakens certain immune responses.

Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.

Topical immunotherapy, especially with DPCP, is effective for treating severe alopecia areata.

New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

More effective methods are needed to prevent hair loss from chemotherapy.

Hair loss from immunosuppressive drugs in transplant patients can affect well-being and treatment adherence, so personalized management is important.

Hedgehog pathway inhibitors could be effective in treating melanoma.

Nanotechnology could improve treatment for scars and atopic dermatitis by targeting skin issues more effectively.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

Imiquimod may be a better non-surgical treatment for cervical pre-cancer, but its effectiveness for vaginal pre-cancer is unclear, and it has some side effects.

Atopic dermatitis and alopecia areata share immune and genetic factors, and targeted therapies may help both.

Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.

Nanocarriers improve skin disease treatment by targeting hair follicles effectively.

New treatments for alopecia areata show promise but need ongoing use and have infection risks.

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

Photobiomodulation therapy shows promise in treating various health conditions by using specific light wavelengths.

New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.

Thermoresponsive nanogels show promise for delivering medicine through the skin but need more safety testing and regulatory approval before clinical use.

Some cells may slow melanoma growth, a protein could affect skin pigmentation, a gene-silencing method might treat hair defects, skin bacteria changes likely result from eczema, and a defensin protein could help treat multiple sclerosis.

Therapy lowers IgM levels in dogs with severe dermatitis but not in mild cases.

Immune cells affect hair growth and could lead to new hair loss treatments.

DPCP immunotherapy is effective for alopecia areata, and understanding influencing factors can improve treatment and satisfaction.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

IVIG therapy was linked to hair regrowth in two patients with hair loss, but it's not recommended due to its risks and costs.

COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.